| scholarly article | Q13442814 |
| P50 | author | Igor Feoktistov | Q63561885 |
| P2093 | author name string | Anna E Goldstein | |
| Italo Biaggioni | |||
| Sergey Ryzhov | |||
| Sergey V Novitskiy | |||
| David P Carbone | |||
| Mikhail M Dikov | |||
| Rinat Zaynagetdinov | |||
| P2860 | cites work | Adenosine receptors in colon carcinoma tissues and colon tumoral cell lines: focus on the A(3) adenosine subtype | Q79909349 |
| Adenosine A(2b) receptor is highly expressed in human hepatocellular carcinoma | Q79915871 | ||
| Chronic immune activation and inflammation as the cause of malignancy | Q24648532 | ||
| International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors | Q28209239 | ||
| Mast cell-mediated stimulation of angiogenesis: cooperative interaction between A2B and A3 adenosine receptors | Q28211407 | ||
| Opposing roles of netrin-1 and the dependence receptor DCC in cancer cell invasion, tumor growth and metastasis | Q28291163 | ||
| Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury | Q28585044 | ||
| The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies | Q29614311 | ||
| Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells | Q32065053 | ||
| Tumor-promoting functions of adenosine | Q34047331 | ||
| The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2a adenosine receptor antagonist. | Q34379961 | ||
| A2A adenosine receptor protects tumors from antitumor T cells. | Q35016529 | ||
| Human breast cancer cell line MDA-MB-231 expresses endogenous A2B adenosine receptors mediating a Ca2+ signal. | Q35048860 | ||
| A glance at adenosine receptors: novel target for antitumor therapy | Q35556102 | ||
| Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma | Q35764956 | ||
| Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. | Q35900957 | ||
| A2A adenosine receptors and C/EBPbeta are crucially required for IL-10 production by macrophages exposed to Escherichia coli | Q36007662 | ||
| Role of immature myeloid cells in mechanisms of immune evasion in cancer | Q36208862 | ||
| Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression | Q36279859 | ||
| Monocyte/macrophage infiltration in tumors: modulators of angiogenesis | Q36602360 | ||
| Hypoxia-dependent anti-inflammatory pathways in protection of cancerous tissues | Q36778743 | ||
| Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells | Q40135122 | ||
| Characterization of adenosine receptors in the human bladder carcinoma T24 cell line | Q40297237 | ||
| Host cyclooxygenase-2 modulates carcinoma growth. | Q40365112 | ||
| Gs protein-coupled adenosine receptor signaling and lytic function of activated NK cells | Q40370352 | ||
| Pharmacological characterization of adenosine A2B receptors: studies in human mast cells co-expressing A2A and A2B adenosine receptor subtypes. | Q41056524 | ||
| Adenosine A2B receptors | Q41689723 | ||
| Differential expression of adenosine receptors in human endothelial cells: role of A2B receptors in angiogenic factor regulation | Q43928343 | ||
| Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses | Q45020410 | ||
| Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation | Q45195923 | ||
| Role of adenosine receptors in the regulation of angiogenic factors and neovascularization in hypoxia. | Q54046112 | ||
| Adenosine metabolism and cancer. Focus on “Adenosine downregulates DPPIV on HT-29 colon cancer cells by stimulating protein tyrosine phosphatases and reducing ERK1/2 activity via a novel pathway” | Q57374645 | ||
| Characterization of adenosine receptors in human erythroleukemia cells and platelets: further evidence for heterogeneity of adenosine A2 receptor subtypes | Q70462241 | ||
| Adenosine receptor activation induces vascular endothelial growth factor in human retinal endothelial cells | Q73082820 | ||
| The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine | Q73470605 | ||
| Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo | Q77620517 | ||
| P433 | issue | 9 | |
| P304 | page(s) | 987-995 | |
| P577 | publication date | 2008-09-01 | |
| P1433 | published in | Neoplasia | Q2962042 |
| P1476 | title | Host A(2B) adenosine receptors promote carcinoma growth | |
| P478 | volume | 10 |
| Q26749571 | A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment |
| Q37373680 | A(2B) adenosine receptors in immunity and inflammation. |
| Q39793029 | A(2B) and A(3) adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin. |
| Q36218394 | A(₂B)AR expression in non-immune cells plays an important role in the development of murine colitis |
| Q38900954 | A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer |
| Q34546999 | A2B adenosine receptor blockade inhibits growth of prostate cancer cells. |
| Q37680218 | ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment |
| Q37399268 | Adenosine A(3) receptor suppresses prostate cancer metastasis by inhibiting NADPH oxidase activity |
| Q38406861 | Adenosine A2A and A2B receptor expression in neuroendocrine tumours: potential targets for therapy |
| Q28074665 | Adenosine A2B Receptor: From Cell Biology to Human Diseases |
| Q30416420 | Adenosine A2B receptor blockade slows growth of bladder and breast tumors |
| Q41976027 | Adenosine A2B receptors on cardiac stem cell antigen (Sca)-1-positive stromal cells play a protective role in myocardial infarction. |
| Q90004707 | Adenosine Blockage in Tumor Microenvironment and Improvement of Cancer Immunotherapy |
| Q39148961 | Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer. |
| Q42059361 | Adenosine and its receptors as therapeutic targets: An overview |
| Q37309945 | Adenosine augments IL-10-induced STAT3 signaling in M2c macrophages |
| Q37650141 | Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model |
| Q37565195 | Adenosine receptors in wound healing, fibrosis and angiogenesis. |
| Q37645138 | Adenosine receptors: expression, function and regulation |
| Q35566772 | Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells |
| Q45737780 | Anti-CD73 therapy impairs tumor angiogenesis |
| Q37448109 | Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma. |
| Q34091467 | CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice |
| Q35015717 | CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice |
| Q36038399 | CD73 promotes tumor growth and metastasis |
| Q94464383 | CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers |
| Q38711094 | CD73-adenosine: a next-generation target in immuno-oncology |
| Q47437537 | Characterisation of endogenous A2A and A2B receptor-mediated cyclic AMP responses in HEK 293 cells using the GloSensor™ biosensor: Evidence for an allosteric mechanism of action for the A2B-selective antagonist PSB 603. |
| Q28072162 | Cyclic AMP Represents a Crucial Component of Treg Cell-Mediated Immune Regulation |
| Q92735135 | Development of multifunctional Overhauser-enhanced magnetic resonance imaging for concurrent in vivo mapping of tumor interstitial oxygenation, acidosis and inorganic phosphate concentration |
| Q24628746 | Dinosaurs and ancient civilizations: reflections on the treatment of cancer |
| Q33598627 | Discovery of LAS101057: A Potent, Selective, and Orally Efficacious A2B Adenosine Receptor Antagonist |
| Q41545207 | Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor |
| Q38907149 | Expression of adenosine receptor subclasses in malignant and adjacent normal human prostate tissues. |
| Q37775889 | Extracellular adenosine triphosphate and adenosine in cancer. |
| Q33878542 | Extracellular adenosine-mediated modulation of regulatory T cells |
| Q90663193 | Focusing on Adenosine Receptors as a Potential Targeted Therapy in Human Diseases |
| Q34695338 | Growth and metastasis of B16-F10 melanoma cells is not critically dependent on host CD73 expression in mice |
| Q92361171 | Hypoxia Compromises Anti-Cancer Immune Responses |
| Q34038901 | Immunity, inflammation and cancer: a leading role for adenosine |
| Q38215678 | Immunoregulatory activity of adenosine and its role in human cancer progression |
| Q28818464 | Interstitial Inorganic Phosphate as a Tumor Microenvironment Marker for Tumor Progression |
| Q36153376 | Introduction to adenosine receptors as therapeutic targets |
| Q38986357 | Latest QSAR study of adenosine A[Formula: see text] receptor affinity of xanthines and deazaxanthines. |
| Q38801257 | Ligand-Independent Adenosine A2B Receptor Constitutive Activity as a Promoter of Prostate Cancer Cell Proliferation |
| Q36296504 | Multivalent Forms of the Notch Ligand DLL-1 Enhance Antitumor T-cell Immunity in Lung Cancer and Improve Efficacy of EGFR-Targeted Therapy |
| Q36413809 | Myeloid-derived suppressor cells contribute to A2B adenosine receptor-induced VEGF production and angiogenesis in a mouse melanoma model |
| Q30484000 | Neoplasia: the second decade |
| Q34027829 | Probing biased/partial agonism at the G protein-coupled A(2B) adenosine receptor |
| Q24618782 | Purinergic signalling and cancer |
| Q37876538 | Regulation of leukocyte function by adenosine receptors |
| Q36070200 | Regulation of macrophage function by adenosine |
| Q35996708 | Role of A2B adenosine receptors in regulation of paracrine functions of stem cell antigen 1-positive cardiac stromal cells |
| Q37405416 | Role of JunB in adenosine A2B receptor-mediated vascular endothelial growth factor production. |
| Q28393883 | Role of TGF-β signaling in generation of CD39+CD73+ myeloid cells in tumors |
| Q37108355 | Role of adenosine A(2B) receptors in inflammation |
| Q53047113 | Small Molecules Drive Big Improvements in Immuno-Oncology Therapies. |
| Q28550667 | Specific Activation of A3, A2A and A1 Adenosine Receptors in CD73-Knockout Mice Affects B16F10 Melanoma Growth, Neovascularization, Angiogenesis and Macrophage Infiltration |
| Q93062525 | Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function |
| Q38209586 | Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer |
| Q46140918 | Targeting immunosuppressive adenosine in cancer |
| Q52323624 | Targeting the Adenosinergic Axis in Chronic Lymphocytic Leukemia: A Way to Disrupt the Tumor Niche? |
| Q42069712 | Targeting the adenosine A2b receptor in the tumor microenvironment overcomes local immunosuppression by myeloid-derived suppressor cells. |
| Q36620552 | Targeting the hypoxia-adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer |
| Q48191363 | The Hypoxia-Adenosine Link during Intestinal Inflammation. |
| Q37478602 | The War on Cancer rages on. |
| Q96230894 | The adenosine pathway in immuno-oncology |
| Q39161005 | The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets |
| Q38767477 | The role of adenosine and adenosine receptors in the immunopathogenesis of multiple sclerosis. |
Search more.